MDxHealth says U.S. meeting confirms test strength BRUSSELS (Reuters) - Belgian biotech company MDxHealth said on Monday two presentations set to be delivered at a leading U.S. convention would confirm that its prostate cancer test helps urologists rule out unnecessary repeat biopsies. The molecular diagnostic company, which develops tests for cancer, said two presentations would be made supporting its ConfirmMDx test at the American Urology Association annual meeting on May 4-8. ConfirmMDx, MDxHealth's first commercial product, aims to distinguish patients with a true-negative biopsy from those who may have undetected cancer. Reporting by Philip Blenkinsop